Data from a recent study, published in the August issue of the Public Library of Science Pathogens, has shown an anti-inflammatory and pathogen-protection benefit for Bifidobacterium infantis 35624.
The study examined the effect of Bifidobacterium infantis 35624 administration on Salmonella typhimurium, harmful bacteria that can cause intestinal infections and trigger the body's inflammatory response. The bifidobacterium, a probiotic strain isolated from healthy human gastrointestinal tissue, was administered to mice in freeze-dried powder at least three weeks prior to salmonella infection. Animals that received the powder showed dramatically increased numbers of certain immune cells that control the immune system response to harmful pathogens, in this case Salmonella.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze